Skip to main content
STTK
NASDAQ Life Sciences

Shattuck Q3 Loss Widens to $25.2M as SL-325 Phase 2b Crohn's Trial Begins

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.5
Mkt Cap
$516.871M
52W Low
$1.72
52W High
$8.33
52W Position info
220% above low
Off High info
34% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

STTK has more than doubled off its 52-week low of $1.72.

Summary

Shattuck reported a Q3 2026 net loss of $25.2 million as R&D jumped to $21.6 million, and said $196.3 million in cash funds operations into 2029. The company initiated its Phase 2b Crohn's trial of SL-325 and plans to start a Phase 2 HS trial in Q4 2026.


Key Events · Earnings and Guidance · STTK

  • Q3 Loss Widens on R&D Step-Up

    Net loss was $25.2 million, or $0.14 per share, versus $10.1 million a year earlier, as R&D rose to $21.6 million from $7.6 million.

  • Cash Runway Extended Into 2029

    Cash, equivalents and short-term investments totaled $196.3 million at September 30, 2026, up from $86.1 million a year earlier, funding operations into 2029.

  • Phase 2b Crohn's Trial Initiated

    RECEPTIVE-CD1 randomizes approximately 232 patients 1:1:1:1 across three SL-325 dose levels and placebo, with endoscopic response at 12 weeks as the primary endpoint and data expected in the first half of 2028.

  • HS Phase 2 Planned for Q4 2026

    RECEPTIVE-HS1 will test two dose levels versus placebo in approximately 150 patients with HiSCR50 at Week 16 as the primary endpoint; an IND was submitted in October 2026 and data are expected in the first half of 2028.


Analysis · STTK · Life Sciences

The quarterly loss widened sharply as R&D spending nearly tripled to $21.6 million, the cost of moving SL-325 into a 232-patient Phase 2b Crohn's trial and preparing a second Phase 2 in hidradenitis suppurativa. Against that burn, $196.3 million in cash and investments is expected to fund operations into 2029, so the spending increase is a deliberate pipeline build rather than a runway problem. The key read-through is timing: both SL-325 datasets land in the first half of 2028, leaving a long gap before the next major clinical catalyst.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STTK was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $516.9M. The 52-week trading range was $1.72 to $8.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STTK - Latest Insights

STTK
Nov 05, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.39 info
Change: -$1.11 (-20%) info
Market Cap: $463.384M info
STTK
Oct 01, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.79
Real-time Price: $4.39 info
Change: -$2.40 (-35%) info
Market Cap: $463.384M info
STTK
Aug 11, 2026, 6:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.39 info
Change: -$2.61 (-37%) info
Market Cap: $463.384M info
STTK
Aug 11, 2026, 6:57 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.39 info
Change: -$2.61 (-37%) info
Market Cap: $463.384M info
STTK
Aug 11, 2026, 6:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.39 info
Change: -$2.61 (-37%) info
Market Cap: $463.384M info